Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are FUSN, BSX, ARVN, ISRG, ITCI, and represent 19.60% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: MRK (+$66M), Cg Oncology (+$64M), ILMN (+$64M), ISRG (+$56M), CYTK (+$54M), ALPN (+$47M), DNTH (+$45M), ALNY (+$36M), ITCI (+$34M), RGNX (+$27M).
- Started 32 new stock positions in IMUX, DXCM, KROS, CYTK, ESTA, RDNT, CYBN, COGT, GKOS, JANX.
- Reduced shares in these 10 stocks: TMO (-$85M), Karuna Therapeutics Ord (-$65M), CI (-$60M), BHVN (-$59M), , , HUM (-$46M), BDX (-$40M), SNDX (-$37M), DHR (-$37M).
- Sold out of its positions in A, AKRO, AMLX, ARGX, ARWR, BDX, Caremax, CERE, CMPX, CRNX. HUM, ImmunoGen, NTLA, Karuna Therapeutics Ord, TVTX, UNH, VRNA, ZTS.
- Avidity Partners Management was a net seller of stock by $-135M.
- Avidity Partners Management has $2.9B in assets under management (AUM), dropping by 5.82%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 87 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Fusion Pharmaceuticals (FUSN) | 4.8 | $139M | 6.5M | 21.32 |
|
|
| Boston Scientific Corporation (BSX) | 4.6 | $134M | +3% | 2.0M | 68.49 |
|
| Arvinas Ord (ARVN) | 4.2 | $123M | 3.0M | 41.28 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.1 | $90M | +165% | 226k | 399.09 |
|
| Intra Cellular Therapies (ITCI) | 2.9 | $83M | +69% | 1.2M | 69.20 |
|
| Dianthus Therapeutics (DNTH) | 2.8 | $82M | +123% | 2.7M | 30.00 |
|
| Acadia Healthcare (ACHC) | 2.7 | $80M | -13% | 1.0M | 79.22 |
|
| Neurocrine Biosciences (NBIX) | 2.5 | $74M | -18% | 537k | 137.92 |
|
| Natera (NTRA) | 2.5 | $74M | -27% | 803k | 91.46 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.4 | $70M | +19% | 584k | 120.42 |
|
| Avantor (AVTR) | 2.4 | $69M | +27% | 2.7M | 25.57 |
|
| Cigna Corp (CI) | 2.3 | $67M | -47% | 185k | 363.19 |
|
| Merck & Co (MRK) | 2.3 | $66M | NEW | 502k | 131.95 |
|
| Regeneron Pharmaceuticals (REGN) | 2.3 | $65M | 68k | 962.49 |
|
|
| Cg Oncology | 2.2 | $64M | NEW | 1.5M | 43.90 |
|
| Illumina (ILMN) | 2.2 | $64M | NEW | 464k | 137.32 |
|
| Tenet Healthcare Corp Com New (THC) | 2.2 | $63M | -30% | 601k | 105.11 |
|
| Align Technology (ALGN) | 2.1 | $62M | +21% | 189k | 327.92 |
|
| Syndax Pharmaceuticals (SNDX) | 2.0 | $57M | -38% | 2.4M | 23.80 |
|
| Eli Lilly & Co. (LLY) | 1.9 | $55M | -17% | 70k | 777.96 |
|
| Cytokinetics Com New (CYTK) | 1.8 | $54M | NEW | 766k | 70.11 |
|
| United Therapeutics Corporation (UTHR) | 1.7 | $50M | -8% | 217k | 229.72 |
|
| Alpine Immune Sciences (ALPN) | 1.6 | $47M | NEW | 1.2M | 39.64 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.5 | $44M | +10% | 934k | 46.69 |
|
| CVS Caremark Corporation (CVS) | 1.5 | $44M | -26% | 545k | 79.76 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.5 | $44M | -39% | 1.0M | 42.86 |
|
| Surgery Partners (SGRY) | 1.5 | $43M | +23% | 1.4M | 29.83 |
|
| Abbvie (ABBV) | 1.4 | $41M | -20% | 227k | 182.10 |
|
| Blueprint Medicines (BPMC) | 1.4 | $40M | -30% | 426k | 94.86 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.3 | $38M | -2% | 668k | 56.09 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.3 | $36M | NEW | 243k | 149.45 |
|
| Danaher Corporation (DHR) | 1.2 | $36M | -50% | 144k | 249.72 |
|
| Ideaya Biosciences (IDYA) | 1.2 | $35M | -47% | 800k | 43.88 |
|
| Axsome Therapeutics (AXSM) | 1.2 | $34M | -6% | 431k | 79.80 |
|
| Xenon Pharmaceuticals (XENE) | 1.1 | $31M | -12% | 710k | 43.05 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 1.0 | $30M | +26% | 480k | 62.24 |
|
| Caribou Biosciences (CRBU) | 1.0 | $30M | -9% | 5.8M | 5.14 |
|
| Mirum Pharmaceuticals (MIRM) | 1.0 | $29M | 1.1M | 25.12 |
|
|
| Rocket Pharmaceuticals (RCKT) | 1.0 | $28M | -40% | 1.0M | 26.94 |
|
| Regenxbio Inc equity us cm (RGNX) | 0.9 | $27M | NEW | 1.3M | 21.07 |
|
| Apogee Therapeutics (APGE) | 0.9 | $26M | NEW | 385k | 66.45 |
|
| Neumora Therapeutics (NMRA) | 0.9 | $25M | -9% | 1.8M | 13.75 |
|
| Dex (DXCM) | 0.8 | $25M | NEW | 177k | 138.70 |
|
| Neurogene (NGNE) | 0.8 | $24M | 465k | 50.90 |
|
|
| Jasper Therapeutics Com New (JSPR) | 0.8 | $22M | NEW | 760k | 29.36 |
|
| Immunome (IMNM) | 0.7 | $22M | -34% | 874k | 24.68 |
|
| Thermo Fisher Scientific (TMO) | 0.7 | $21M | -79% | 37k | 581.21 |
|
| Glaukos (GKOS) | 0.7 | $21M | NEW | 224k | 94.29 |
|
| Revolution Medicines (RVMD) | 0.7 | $21M | +958% | 635k | 32.23 |
|
| Vaxcyte (PCVX) | 0.7 | $19M | -50% | 284k | 68.31 |
|
| Immunocore Hldgs Ads (IMCR) | 0.6 | $19M | -4% | 286k | 65.00 |
|
| Phathom Pharmaceuticals (PHAT) | 0.6 | $18M | 1.7M | 10.62 |
|
|
| McKesson Corporation (MCK) | 0.6 | $18M | -61% | 33k | 536.85 |
|
| Vera Therapeutics Cl A (VERA) | 0.6 | $17M | NEW | 384k | 43.12 |
|
| Immunovant (IMVT) | 0.6 | $16M | +106% | 505k | 32.31 |
|
| Privia Health Group (PRVA) | 0.5 | $15M | -40% | 764k | 19.59 |
|
| Janux Therapeutics (JANX) | 0.5 | $15M | NEW | 384k | 37.65 |
|
| Cybin Ord (CYBN) | 0.5 | $14M | NEW | 35M | 0.41 |
|
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.5 | $14M | 361k | 38.82 |
|
|
| Prime Medicine (PRME) | 0.5 | $14M | NEW | 2.0M | 7.00 |
|
| Keros Therapeutics (KROS) | 0.5 | $14M | NEW | 210k | 66.20 |
|
| Astria Therapeutics (ATXS) | 0.5 | $14M | NEW | 982k | 14.07 |
|
| Ac Immune Sa SHS (ACIU) | 0.5 | $13M | 4.5M | 2.96 |
|
|
| Karyopharm Therapeutics (KPTI) | 0.4 | $13M | 8.3M | 1.51 |
|
|
| Immunic (IMUX) | 0.4 | $12M | NEW | 8.9M | 1.32 |
|
| RadNet (RDNT) | 0.4 | $12M | NEW | 238k | 48.66 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.4 | $12M | NEW | 225k | 50.90 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.4 | $11M | NEW | 475k | 23.65 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $11M | NEW | 589k | 18.49 |
|
| Astrazeneca Sponsored Adr (AZN) | 0.4 | $11M | NEW | 160k | 67.75 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.3 | $9.0M | 1.7M | 5.35 |
|
|
| Ionis Pharmaceuticals (IONS) | 0.2 | $5.6M | NEW | 130k | 43.35 |
|
| Century Therapeutics (IPSC) | 0.2 | $5.1M | -9% | 1.2M | 4.18 |
|
| Kyverna Therapeutics | 0.2 | $5.0M | NEW | 202k | 24.84 |
|
| Emergent BioSolutions (EBS) | 0.2 | $4.8M | NEW | 1.9M | 2.53 |
|
| Kezar Life Sciences (KZR) | 0.2 | $4.5M | 5.0M | 0.90 |
|
|
| Biohaven (BHVN) | 0.1 | $4.1M | -93% | 75k | 54.69 |
|
| An2 Therapeutics (ANTX) | 0.1 | $3.7M | 1.2M | 3.25 |
|
|
| Ginkgo Bioworks Holdings Cl A Shs (DNA) | 0.1 | $3.5M | NEW | 3.0M | 1.16 |
|
| X4 Pharmaceuticals (XFOR) | 0.1 | $3.4M | NEW | 2.4M | 1.39 |
|
| Cogent Biosciences (COGT) | 0.1 | $3.0M | NEW | 446k | 6.72 |
|
| Pacific Biosciences of California (PACB) | 0.1 | $2.5M | NEW | 675k | 3.75 |
|
| Scynexis Com New (SCYX) | 0.1 | $2.1M | 1.4M | 1.47 |
|
|
| Kodiak Sciences (KOD) | 0.1 | $1.6M | NEW | 300k | 5.26 |
|
| Hyperfine Com Cl A (HYPR) | 0.0 | $1.2M | 1.2M | 1.00 |
|
|
| Caremax Cl A New (CMAX) | 0.0 | $102k | NEW | 21k | 4.82 |
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $27k | 90k | 0.30 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2024 Q1 filed May 15, 2024
- Avidity Partners Management 2023 Q4 filed Feb. 14, 2024
- Avidity Partners Management 2023 Q3 filed Nov. 14, 2023
- Avidity Partners Management 2023 Q2 filed Aug. 14, 2023
- Avidity Partners Management 2023 Q1 filed May 15, 2023
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023
- Avidity Partners Management 2022 Q3 filed Nov. 14, 2022
- Avidity Partners Management 2022 Q2 filed Aug. 15, 2022
- Avidity Partners Management 2022 Q1 filed May 16, 2022
- Avidity Partners Management 2021 Q4 filed Feb. 14, 2022
- Avidity Partners Management 2021 Q3 filed Nov. 15, 2021
- Avidity Partners Management 2021 Q2 filed Aug. 16, 2021
- Avidity Partners Management 2021 Q1 filed May 17, 2021
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020